Celldex Therapeutics, Inc. (CLDX)
NASDAQ: CLDX · Real-Time Price · USD
25.25
-0.15 (-0.57%)
Nov 5, 2024, 3:49 PM EST - Market open
Celldex Therapeutics Cash Flow Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | 2018 - 2014 |
|---|---|---|---|---|---|---|---|
Period Ending | Jun '24 Jun 30, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | Dec '19 Dec 31, 2019 | 2018 - 2014 |
| Net Income | -150.22 | -141.43 | -112.33 | -70.51 | -59.78 | -50.88 | Upgrade
|
| Depreciation & Amortization | 3.1 | 3.01 | 2.9 | 3.07 | 3.93 | 4.86 | Upgrade
|
| Loss (Gain) From Sale of Assets | 0.01 | - | 0 | -0.02 | -0.06 | 0.01 | Upgrade
|
| Asset Writedown & Restructuring Costs | - | - | - | 3.5 | 18 | 1.8 | Upgrade
|
| Loss (Gain) From Sale of Investments | -11.86 | -6.22 | 0.84 | -3.21 | -0.73 | -1.14 | Upgrade
|
| Stock-Based Compensation | 29.18 | 23.89 | 15.61 | 8.95 | 3.92 | 4.55 | Upgrade
|
| Other Operating Activities | - | - | -6.86 | -1.63 | -5.39 | -1.29 | Upgrade
|
| Change in Accounts Receivable | -1.42 | -2.28 | -0.18 | 1.57 | -0.79 | 2.27 | Upgrade
|
| Change in Accounts Payable | 9.29 | 9.38 | 3.12 | 3.65 | 1.64 | -0.32 | Upgrade
|
| Change in Other Net Operating Assets | 0.43 | 6.36 | -6.85 | -6.28 | -1.15 | -6.28 | Upgrade
|
| Operating Cash Flow | -121.49 | -107.29 | -103.73 | -60.91 | -40.4 | -46.42 | Upgrade
|
| Capital Expenditures | -1.44 | -1.82 | -1.83 | -1.25 | -1.55 | -0.73 | Upgrade
|
| Sale of Property, Plant & Equipment | - | - | 0.07 | 0.03 | 0.06 | 0.02 | Upgrade
|
| Investment in Securities | -520.01 | -103.96 | 91.7 | -214.93 | -96.72 | 17.79 | Upgrade
|
| Investing Cash Flow | -521.45 | -105.78 | 89.94 | -216.16 | -98.22 | 17.08 | Upgrade
|
| Short-Term Debt Issued | - | - | - | - | 2.96 | - | Upgrade
|
| Total Debt Issued | - | - | - | - | 2.96 | - | Upgrade
|
| Short-Term Debt Repaid | - | - | - | - | -2.96 | - | Upgrade
|
| Total Debt Repaid | - | - | - | - | -2.96 | - | Upgrade
|
| Issuance of Common Stock | 657.46 | 218.46 | 4.08 | 272.37 | 171.23 | 16.26 | Upgrade
|
| Financing Cash Flow | 657.46 | 218.46 | 4.08 | 272.37 | 171.23 | 16.26 | Upgrade
|
| Net Cash Flow | 14.52 | 5.39 | -9.71 | -4.69 | 32.6 | -13.08 | Upgrade
|
| Free Cash Flow | -122.93 | -109.11 | -105.56 | -62.16 | -41.96 | -47.15 | Upgrade
|
| Free Cash Flow Margin | -1480.57% | -1585.20% | -4478.57% | -1336.44% | -565.60% | -1319.51% | Upgrade
|
| Free Cash Flow Per Share | -2.19 | -2.25 | -2.25 | -1.45 | -1.42 | -3.25 | Upgrade
|
| Levered Free Cash Flow | -56.81 | -46.7 | -58.03 | -29.71 | -22.62 | -25.56 | Upgrade
|
| Unlevered Free Cash Flow | -56.81 | -46.7 | -58.03 | -29.71 | -22.62 | -25.56 | Upgrade
|
| Change in Net Working Capital | -14.42 | -16.99 | 7.77 | -2.74 | -2.07 | 0.16 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.